Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 6.69
(-3.04%)
CNY 6.69
(-3.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -90.79 Million CNY | 44.66% |
| 2022 | -134.37 Million CNY | -188.4% |
| 2021 | 132.71 Million CNY | -42.16% |
| 2020 | 251.86 Million CNY | -13.24% |
| 2019 | 288.77 Million CNY | 13.56% |
| 2018 | 249.41 Million CNY | 10.28% |
| 2017 | 215.06 Million CNY | 4.67% |
| 2016 | 209.76 Million CNY | -1.74% |
| 2015 | 208.29 Million CNY | -0.63% |
| 2014 | 201.18 Million CNY | 50.81% |
| 2013 | 141.64 Million CNY | -4.54% |
| 2012 | 142.61 Million CNY | 134.44% |
| 2011 | 63.29 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -18.68 Million CNY | -33.79% |
| 2024 Q1 | -13.96 Million CNY | 64.93% |
| 2024 Q3 | 2.54 Million CNY | 91.73% |
| 2023 Q1 | -16.67 Million CNY | 84.15% |
| 2023 FY | - CNY | 44.66% |
| 2023 Q4 | -39.71 Million CNY | -237.98% |
| 2023 Q3 | -11.75 Million CNY | 74.05% |
| 2023 Q2 | -45.29 Million CNY | -171.67% |
| 2022 Q4 | -105.2 Million CNY | 3.6% |
| 2022 Q3 | -109.13 Million CNY | -583.56% |
| 2022 Q2 | 22.56 Million CNY | -10.35% |
| 2022 Q1 | 25.17 Million CNY | 628.95% |
| 2022 FY | - CNY | -188.4% |
| 2021 Q1 | 47.8 Million CNY | 102.52% |
| 2021 Q4 | -4.75 Million CNY | -126.51% |
| 2021 Q3 | 17.95 Million CNY | -45.77% |
| 2021 Q2 | 33.09 Million CNY | -30.76% |
| 2021 FY | - CNY | -42.16% |
| 2020 Q3 | 87.59 Million CNY | 561.08% |
| 2020 FY | - CNY | -13.24% |
| 2020 Q2 | 13.24 Million CNY | -82.38% |
| 2020 Q1 | 75.19 Million CNY | 35.38% |
| 2020 Q4 | 23.6 Million CNY | -73.05% |
| 2019 Q4 | 55.54 Million CNY | 15.54% |
| 2019 Q2 | 91.84 Million CNY | 116.67% |
| 2019 Q1 | 42.38 Million CNY | 64.84% |
| 2019 Q3 | 48.07 Million CNY | -47.66% |
| 2019 FY | - CNY | 13.56% |
| 2018 Q4 | 25.71 Million CNY | -75.13% |
| 2018 FY | - CNY | 10.28% |
| 2018 Q3 | 103.41 Million CNY | 87.7% |
| 2018 Q2 | 55.09 Million CNY | 105.46% |
| 2018 Q1 | 26.81 Million CNY | -69.84% |
| 2017 Q1 | 26.73 Million CNY | -72.81% |
| 2017 Q2 | 42.63 Million CNY | 59.5% |
| 2017 Q3 | 37.99 Million CNY | -10.88% |
| 2017 Q4 | 88.91 Million CNY | 133.98% |
| 2017 FY | - CNY | 4.67% |
| 2016 Q1 | 25.83 Million CNY | -64.15% |
| 2016 FY | - CNY | -1.74% |
| 2016 Q2 | 61.6 Million CNY | 138.43% |
| 2016 Q3 | 30.09 Million CNY | -51.14% |
| 2016 Q4 | 98.32 Million CNY | 226.67% |
| 2015 Q4 | 72.07 Million CNY | 101.78% |
| 2015 Q3 | 35.71 Million CNY | 386.09% |
| 2015 Q2 | -12.48 Million CNY | -112.23% |
| 2015 Q1 | 102.11 Million CNY | 16.83% |
| 2015 FY | - CNY | -0.63% |
| 2014 Q2 | -33.2 Million CNY | -130.92% |
| 2014 FY | - CNY | 50.81% |
| 2014 Q4 | 87.4 Million CNY | 225.07% |
| 2014 Q1 | 107.42 Million CNY | 0.0% |
| 2014 Q3 | 26.88 Million CNY | 180.96% |
| 2013 FY | - CNY | -4.54% |
| 2012 FY | - CNY | 134.44% |
| 2011 FY | - CNY | 0.0% |